Loading
Rock Immune
Rock Immune is a Denver company making immunotoxins: proteins that carry a disabled bacterial toxin straight to cancer cells. Its lead candidate, Rock425, is aimed at cutaneous T-cell lymphoma, a lymphoma of the skin.
Also called: Rock Immune, Inc.
Overview
Rock Immune, Inc. describes itself as an early-stage biopharmaceutical company developing diphtheria toxin-based recombinant immunotoxins for cancer and autoimmune disease, made in a proprietary diphtheria toxin-resistant Pichia pastoris yeast system. Its lead candidate Rock425 is a CCR4-IL2 bispecific immunotoxin for cutaneous T-cell lymphoma, which the company reports was effective in a mouse model. A 2026 National Cancer Institute STTR award funds a bivalent CD47 immunotoxin for T-cell acute lymphoblastic leukaemia.
Headquarters
Denver, CO, US
Scorecard
All companies#692of 1706 companies, score 4
- targets +2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR (R41) award 1R41CA309908-01: Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalRecombinant immunotoxin (bispecific fusion protein)
Rock425 is an experimental immunotoxin from Rock Immune that carries a disabled diphtheria toxin to malignant T cells. It is being developed for cutaneous T-cell lymphoma and has not yet been tested in people.
Notes
- Company website and the NIH RePORTER record read on 4 November 2026. The website also mentions an earlier NCI STTR Fast Track grant of USD 2.4 million awarded in July 2021, not read on RePORTER. Founding year not stated.
Connected
6Similar pages
cancers
fronts
targets
drugs
PreclinicalRecombinant immunotoxin (bispecific fusion protein)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nih.gov · 1
rockimmune.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/